Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | CLK1 | P49759 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3547916 | 0.94 | CSNK1D (0.48) | NPC1RAB9AKMT2ACLK1MEN1 | |
| SCHEMBL3548167 | 0.93 | SMN1; SMN2 (0.46) | NPC1RAB9AKMT2ACLK1MEN1 | |
| SCHEMBL5790335 | 0.93 | CLK1 (0.46) | NPC1RAB9AKMT2ACLK1MEN1 | |
| SCHEMBL3546643 | 0.93 | CLK1 (0.46) | NPC1RAB9AKMT2ACLK1MEN1 | |
| SCHEMBL3551105 | 0.90 | NPC1 (0.45) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL5197691 | 0.90 | NPC1 (0.45) | NPC1RAB9AKMT2AMEN1MAPT | |
| SCHEMBL3547736 | 0.87 | PDE4A (0.42) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL3550608 | 0.86 | SMN1; SMN2 (0.46) | NPC1RAB9AKMT2AMEN1ALDH1A1 | |
| SCHEMBL5198572 | 0.85 | SMN1; SMN2 (0.47) | KMT2AALDH1A1POLB | |
| SCHEMBL3547751 | 0.85 | SMN1; SMN2 (0.47) | KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2005-02-03 | — | — | US | claimed |
| US-7696198-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-12-10 | — | — | US | disclosed |
| US-7585882-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | MEMORY PHARMACEUTICALS CORPORATION | 2006-06-22 | — | — | US | disclosed |
| EP-1613590-A2 | 4-(3,4-DISUBSTITUTED PHENYL)-PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050026913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2004094375-A2 | 4 - (3,4 - DISUBSTITUTED PHENYL) - PYRROLIDIN-2-ONE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE12, PDE3B | NPC1 4678/4885RAB9A 1320/4885KMT2A 1490/4885 |
| US-20060135535-A1 | 4-(substituted-phenyl)-2-pyrrolidinones; reduced emetic side effects; antiinflammatory agents; neurological syndromes, asthma, arthritis | PDE4A, PDE4B, PDE12 | NPC1 4611/4885RAB9A 993/4885KMT2A 1797/4885 |
| US-20090306156-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE5A | NPC1 4183/4885RAB9A 1550/4885KMT2A 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.